2023
Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Lopez-Olivo M, Kachira J, Buni M, Kim S, Lu H, Tayar J, Duhon G, Ruiz J, Bingham C, Calabrese C, Volk R, Suarez-Almazor M. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers 2023, 15: 4004. PMID: 37568819, PMCID: PMC10416973, DOI: 10.3390/cancers15154004.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune-related adverse eventsPre-existing autoimmune diseaseAutoimmune diseasesCheckpoint inhibitorsFlare-upBenefit of immune checkpoint inhibitorsAutoimmune disease flare-upManagement of flare-upsPre-existing autoimmune disordersImmune checkpoint inhibitor treatmentCancer CenterDisease flare-upContext of autoimmune diseasesAutoimmune disease progressionAutoimmune disease treatmentAutoimmune disordersAdverse eventsTreatment modificationOrgan damageComprehensive cancer centerDisease progressionPatientsCancerUS cancer centers
2020
A Case of Acquired Generalized Lipodystrophy Associated with Pembrolizumab in a Patient with Metastatic Malignant Melanoma
Bedrose S, Turin C, Lavis V, Kim S, Thosani S. A Case of Acquired Generalized Lipodystrophy Associated with Pembrolizumab in a Patient with Metastatic Malignant Melanoma. AACE Clinical Case Reports 2020, 6: e40-e45. PMID: 32524008, PMCID: PMC7279776, DOI: 10.4158/accr-2019-0234.Peer-Reviewed Original ResearchImmune-related adverse eventsAcquired generalized lipodystrophyPatients treated with pembrolizumabLoss of subcutaneous fatImmune-checkpoint inhibitorsInitiation of pembrolizumabTreated with pembrolizumabCheckpoint inhibitor therapyMetastatic malignant melanomaAutoimmune hemolytic anemiaUnexplained weight lossWorsening insulin resistanceWorsening hypertriglyceridemiaCheckpoint inhibitorsMetastatic melanomaInhibitor therapyTreat several typesGeneralized lipodystrophyPembrolizumabIrreversible complicationsMalignant melanomaAutoimmune disordersCase reportAdverse eventsHemolytic anemia
2012
Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells
Kinnunen T, Chamberlain N, Morbach H, Choi J, Kim S, Craft J, Mayer L, Cancrini C, Passerini L, Bacchetta R, Ochs HD, Torgerson TR, Meffre E. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood 2012, 121: 1595-1603. PMID: 23223361, PMCID: PMC3587322, DOI: 10.1182/blood-2012-09-457465.Peer-Reviewed Original ResearchConceptsB cell tolerancePeripheral B cell toleranceIPEX patientsRegulatory T cellsAutoreactive B cellsNaive B cellsB cellsT cellsTreg functionAutoreactive mature naive B cellsHuman B cell toleranceForkhead box protein 3 geneHuman regulatory T cellsMature naive B cellsTreg-like cellsCentral B cell toleranceSevere autoimmune disordersT-cell costimulatorTransitional B cellsRegulation of CD40LReactivity of antibodiesDefective Treg functionSingle B cellsPD-1Autoimmune disorders